REGN
Stock Details
REGN is Regeneron Pharmaceuticals, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 649.42$. Average daily volumn in 3 months 704.64k. Market cap 78.74B
Stock symbol : REGN. Exchange : NasdaqGS. Currency : USD Lastest price : 722.37$. Total volume : 650.86k. Market state POST Click reload if you want to check the lastest price on market!!!
Regeneron Pharmaceuticals, Inc. (REGN)
Last Price
722.37$Change
-9.49Volume
650.86k
| Previous Close | 731.86 |
| Open | 731.66 |
| Day Range | 720.14-732.69 |
| Bid | 701.00 x 900 |
| Ask | 722.27 x 800 |
| Volume | 650.86k |
| Average Volume | 704.64k |
| Market Cap | 78.74B |
| Beta | 0.17 |
| 52 Week Range | 538.01-754.67 |
| Trailing P/E | 14.73 |
| Foward P/E | 16.65 |
| Dividend (Yield %) | N/A |
| Ex-Dividend Date | N/A |
Financial Details
Organization
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vei... n occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Market Cap:
78.74BRevenue:
16.07BTotal Assets:
25.43BTotal Cash:
2.89B
News about "Regeneron Pharmaceuticals, Inc."
Regeneron Pharmaceuticals (NASDAQ: REGN)
Source from : The Motley Fool - 2 days ago
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.See details»
Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?
Source from : Nasdaq - 3 days ago
Biotech giant Regeneron Pharmaceuticals REGN witnessed a massive surge in sales in 2021, driven by an exemplary contribution from REGEN-COV, a cocktail of two monoclonal antibodies — casirivimab and ...See details»
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Increased to $970.00 by Analysts at The Goldman Sachs Group
Source from : Defense World - 3 days ago
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) had its price objective raised by The Goldman Sachs Group from $796.00 to $970.00 in a research note released on Monday, Stock Target Advisor ...See details»
Regeneron (REGN) Recently Broke Out Above the 20-Day Moving Average
Source from : YAHOO!Finance - 3 days ago
Regeneron (REGN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, REGN crossed above the 20-day moving average, suggesting a ...See details»
REGN Regeneron Pharmaceuticals, Inc.
Source from : Seeking Alpha - 8 days ago
**NM signifies a non meaningful value. A dash signifies the data is not available.See details»
Insiders who sold Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) earlier year may find some solace in the 4.1% drop
Source from : Yahoo - 10 days ago
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) stock price has dropped 4.1% in the previous week, but insiders who sold US$16m in stock over the past year have had less luck. Given that the ...See details»
Regeneron Pharmaceuticals Whale Trades For October 03
Source from : Benzinga on MSN - 4 days ago
Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on ...See details»
Sequoia Financial Advisors LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Source from : Defense World - 1 days ago
Sequoia Financial Advisors LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 3.4% in the 2nd quarter, according to its most recent 13F filing with the ...See details»
Regeneron Elects Dr. Craig B. Thompson to Board of Directors
Source from : YAHOO!Finance - 4 days ago
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Craig B. Thompson, M.D., has been elected to the Board of Directors, effective immediately. Dr. Thompson has also been appointed to ...See details»
If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now
Source from : Zacks.com on MSN - 3 days ago
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and ...See details»
Regeneron Pharmaceuticals (NASDAQ:REGN) stock performs better than its underlying earnings growth over last three years
Source from : Yahoo! Sports - 23 days ago
To wit, the Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) share price has flown 143% in the last three years. How nice for those who held the stock! It's also good to see the share price up 25% ...See details»
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
Source from : Business Insider - 7 days ago
30, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept ...See details»
10 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital
Source from : Yahoo Finance - 11 hours ago
In this article, we will take a look at some of the notable pharma stocks to buy according to Steven Boyd’s Armistice Capital. To skip our analysis of Steven Boyd’s profile, investment strategy, and ...See details»
Regeneron : FDA Approves Dupixent For Prurigo Nodularis Treatment
Source from : Nasdaq - 9 days ago
(RTTNews) - The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, Regeneron Pharmaceuticals Inc. (REGN) and Sanofi ...See details»